SCHEMBL7536903

SCHEMBL7536903

COc1ccc(OC)c(S(=O)(=O)Nc2ccc(F)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.75
SMN1; SMN2 Q16637 6/20 0.74
KMT2A Q03164 3/20 0.71
MEN1 O00255 2/20 0.71
ALOX12 P18054 1/20 0.71
HTT P42858 1/20 0.71
HPGD P15428 1/20 0.70
ALDH1A1 P00352 3/20 0.69
NPSR1 Q6W5P4 1/20 0.69
TP53 P04637 2/20 0.67
GAA P10253 1/20 0.67
MAPK1 P28482 1/20 0.67
ALPL P05186 1/20 0.67
L3MBTL1 Q9Y468 2/20 0.65
CYP1A2 P05177 1/20 0.64
GLA P06280 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2D6 P10635 1/20 0.64
CYP2C9 P11712 1/20 0.64
PKM P14618 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530465 0.91 SMN1; SMN2 (0.79) LMNASMN1; SMN2KMT2AMEN1ALOX12
SCHEMBL95715 0.86 SMN1; SMN2 (0.71) LMNASMN1; SMN2KMT2AMEN1ALOX12
SCHEMBL7535714 0.86 SMN1; SMN2 (0.72) LMNASMN1; SMN2KMT2AMEN1ALOX12
SCHEMBL5962533 0.86 SMN1; SMN2 (0.71) LMNASMN1; SMN2KMT2AMEN1ALOX12
SCHEMBL7529463 0.86 TP53 (0.80) LMNASMN1; SMN2KMT2AMEN1ALOX12
SCHEMBL7528115 0.86 SMN1; SMN2 (0.72) LMNASMN1; SMN2KMT2AMEN1ALOX12
SCHEMBL14403263 0.85 SMN1; SMN2 (1.00) LMNASMN1; SMN2KMT2AMEN1ALOX12
SCHEMBL23846500 0.84 LMNA (0.73) LMNASMN1; SMN2KMT2AMEN1HTT
SCHEMBL21761109 0.84 LMNA (0.73) LMNASMN1; SMN2KMT2AMEN1ALOX12
SCHEMBL7571589 0.84 LMNA (0.73) LMNASMN1; SMN2KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020183393-A1 Inhibitors of Rho C ICONIX PHARMACEUTICALS INC. 2002-12-05 US disclosed
WO-2002022565-A1 INHIBITORS OF RHO C ICONIX PHARMACEUTICALS, INC. (US) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183393-A1 Inhibitors of Rho C RHOC, ROCK1, RHOA LMNA 2037/4885SMN1; SMN2 2961/4885KMT2A 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.